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Abstract
Background: According to a national reference, 15% of German children and adolescents are overweight
(including obese) and 6.3% are obese. An earlier study analysed the impact of childhood overweight and obesity
on different components of direct medical costs (physician, hospital and therapists). To complement the existing
literature for Germany, this study aims to explore the association of body mass index (BMI) with utilisation of
pharmaceuticals and related costs in German children and adolescents.
Methods: Based on data from 14, 836 respondents aged 3-17 years in the German Interview and Examination
Survey for Children and Adolescents (KiGGS), drug intake and associated costs were estimated using a bottom-up
approach. To investigate the association of BMI with utilisation and costs, univariate analyses and multivariate
generalised mixed models were conducted.
Results: There was no significant difference between BMI groups regarding the probability of drug utilisation.
However, the number of pharmaceuticals used was significantly higher (14%) for obese children than for normal
weight children. Furthermore, there was a trend for more physician-prescribed medication in obese children and
adolescents. Among children with pharmaceutical intake, estimated costs were 24% higher for obese children
compared with the normal weight group.
Conclusions: This is the first study to estimate excess drug costs for obesity based on a representative cross-
sectional sample of the child and adolescent population in Germany. The results suggest that obese children
should be classified as a priority group for prevention. This study complements the existing literature and provides
important information concerning the relevance of childhood obesity as a health problem.
Background
Obesity is one of the biggest public health problems
worldwide, not only in adults but also in children and
adolescents. In the WHO European region, the preva-
lence estimates of overweight (including obesity) in 11-
to 13-year-old children range between 5% and 25% [1].
T h ed a t af r o mt h eG e r m a nI n terview and Examination
Survey for Children and Adolescents (KiGGS) show that,
among 3- to 17-year-olds, 15% are overweight (including
obese) and 6.3% are obese according to a national refer-
ence. Extrapolated to the German population, this leads
to a total of 1.9 million overweight children, including
800, 000 who are obese [2].
Overweight and obesity in adulthood are recognised as
important risk factors for numerous chronic diseases [3].
Obesity in childhood also increases the risk of later mor-
bidities [4,5] and in turn increases the risk of obesity in
adulthood [6]. Moreover, a recently published review
found that childhood obesity already has an immediate
impact on child health [4].
Besides the physical, mental and social health conse-
quences of the obesity epidemic, another concern is the
economic burden related to overweight and obesity.
Focusing on adults, previous empirical research has
demonstrated that overweight and obesity are associated
with a substantial economic burden in terms of excess
healthcare utilisation and productivity losses [7-10].
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any medium, provided the original work is properly cited.Evidence of the short-term excess healthcare costs asso-
ciated with obesity in children and adolescents is ambigu-
ous (for a short review of recent studies, see John et al.
[11]). Although some studies have not found a positive
correlation between costs and body mass index (BMI)
[12,13], in other studies a positive impact was observed
[14-16]. In further studies, this positive relationship was
only visible in subgroups, such as adolescents [17] or
girls [18]. However, comparability between these studies
is difficult because of the use of different methods and
the inclusion of different age groups and cost compo-
nents. One study only found significant differences in
prescription drug costs [15]. In a recently published arti-
cle on the excess costs of overweight and obesity in Ger-
man children and adolescents based on the KIGGS study
[19], we found significantly higher physician costs for
overweight and obese children compared with the nor-
mal weight group. However, this was not evident for
therapist and hospital costs. The component of pharma-
ceutical utilisation and costs was not included in this pre-
vious article. The aim of this study is to fill that gap by
assessing pharmaceutical utilisation and costs associated
with overweight and obesity in children and adolescents
in Germany.
Methods
Data
The data were collected in the German Interview and
Examination Survey for Children and Adolescents
(KiGGS), a population-based survey performed by the
Robert Koch Institute [20]. From May 2003 to May 2006,
a total of 17, 641 children and adolescents aged 0-17
years participated in KiGGS, yielding an overall response
rate of 66.6%. The sample was derived from 167 sample
points (communities) representative of the German
population, stratified by federal state and community
type. Within each sample point, participants were
selected randomly from the official registers of local resi-
dents. Participants beyond 14 years of age and all parents
provided written informed consent prior to the interview
and examination. The survey was approved by the
Federal Office for Data Protection and by the Charité-
Universitätsmedizin Berlin ethics committee. The sam-
pling process and study design are explicitly described in
earlier articles [21-24].
According to a national reference [25], 15% of all chil-
dren in the KiGGS study are classified as overweight
(including obese) and 6.3% as obese. For a detailed
description of the epidemiological results, see Kurth/
Schaffrath-Rosario (2007) [2].
The examination took place in examination centres at
the sample points. Information about sociodemographic
characteristics, health and healthcare utilisation was
obtained from self-administered questionnaires filled in
by the parents. Data on the utilisation of pharmaceuticals
during the previous 7 days were collected by a physician
in a standardised computer-assisted personal interview. If
participants were aged 14 years or older, they were
allowed to answer these questions themselves. A detailed
description of data collection and first results on medica-
tion use has been published previously [26].
Data on height and weight were obtained from physical
examinations [27]. Following the recommendations from
the working group on obesity in children and adolescents
[28], BMI was classified into five groups according to
German age- and sex-specific percentile cut-off points
for children and adolescents: very underweight (< P3),
underweight (P3- < P10), normal weight (P10-P90), over-
weight but not obese (> P90-P97), obese (> P97) [25,27].
Information on parents’ income, occupational status
and education was used to quantify the socioeconomic
status (SES), which was categorised into low, medium
and high SES [21,29-31]. Missing values for SES (n =
370, 2.7%) were imputed using the discriminant function
method from the SAS procedure PROC MI based on
the variables income, insurance status, migrant status,
parents’ BMI, utilisation of regular child health check-
ups, residence (east/west Germany, urban/suburban
area) and health-related quality of life (based on the
KINDL
R total score [32,33]). Children and adolescents
are defined as migrants if they emigrated from another
country and at least one parent was not born in Ger-
many or if both their parents immigrated to Germany
or have no German nationality [34].
The present analyses are restricted to children and
adolescents aged 3-17 years (n = 14, 836), as additional
methodological problems complicate the comparison
with the BMI reference values for younger children [2].
A total of 89 participants with no information on weight
status were excluded from the analyses as well as
another 155 participants with missing information on
the utilisation of pharmaceuticals. This resulted in a
population under research of 14, 592 children and
adolescents.
In order to account for selection bias as far as possi-
ble, post-stratification weights were used, which have
also been applied in the underlying epidemiological stu-
dies to adjust for discrepancies to the German popula-
tion regarding age, sex, region and nationality. The
weights also account for differences in the selection
probability resulting from the sampling method, e.g. the
oversampling in East Germany [23]. A detailed sociode-
mographic and socioeconomic description of the total
study population and the subgroup of children with
drug utilisation is given in Table 1. Percentage and
mean values were calculated using weighted data.
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costs
For the assessment of drug utilisation and related costs,
a rather narrow definition of pharmaceuticals was
applied with reference to §2 German Pharmaceuticals
Act (AMG), and ‘non-pharmaceuticals’ were excluded
based on ATC (anatomic therapeutic chemical classifica-
tion) groups. Specifically, vitamins and dietary supple-
m e n t s( A T CA 1 1 / A 1 2 )w e r ee x c l u d e da sw e l la sA T C
groups V02-V60 (varia), homoeopathic medicines and
teas. Utilisation was defined as the number of pharma-
ceuticals taken within the last 7 days.
Pharmaceutical costs were estimated based on infor-
mation on the name and dosage of drug intake. First,
the drug name was used to derive costs per package. As
suggested by costing guidelines [35,36], the pharmaceu-
ticals were priced with actual 2006 prices for the largest
freely disposable package (N3) according to the national
price list [37] in a conservative base analysis. If the drug
name was imprecise (e.g. ‘cough syrup’), the price of the
most frequently mentioned pharmaceutical in the parti-
cular ATC group was used. If only the agent could be
identified (e.g. ‘acetylsalicylic acid/ASA’), the cheapest
product in the particular ATC group was assumed.
In a second step, total drug costs per week were calcu-
lated as follows: the self-reported number of days of drug
intake per week divided by the number of days a
package’s content was intended for (computed using the
defined daily dose - DDD). This gives the proportion of
the package that was used per week. This proportion was
then multiplied by the package price, resulting in costs
per week. The days of drug intake were documented in
four categories: ‘daily’ and ‘several times a day’ were
interpreted as ‘7 days per week’; ‘often, but not daily’ as
‘1-6 days per week’ resulting in a mean of 3.5 days; and
‘l e s so f t e nt h a no n c ep e rw e e k ’ as ‘once per week’ as it
was mentioned in the context of medicines taken during
the previous 7 days. If information on the frequency of
drug intake was missing (N = 278, about 3% of all 8, 854
cases), the mean frequency in the respective ATC group
was imputed instead.
In order to improve comparability with other studies,
mean costs per week were extrapolated to 1 year by
multiplication with a factor of 52.
To test the sensitivity of utilisation and cost estimates
to changes in the underlying assumptions, univariate
sensitivity analyses were performed. The number of
pharmaceuticals was also analysed without excluding
vitamins, dietary supplement s ,v a r i a ,h o m o e o p a t h i c
medicines and teas. With regard to costs, the prices for
the smallest available package size (N1) were taken
instead to estimate the potential underestimation of
costs due to this assumption. Furthermore, we assessed
the impact of pharmacy discounts and weighting for
seasonal differences in the data collection on the results.
Statistical analysis
Mean and percentage values as well as measures of dis-
persion were calculated using weights to account for
selection bias as far as possible [23].
In univariate analyses, the prevalence of pharmaceutical
intake, in total and separated by ATC groups, was com-
pared between BMI groups, and Chi
2 tests were conducted
to assess the significance of differences. Moreover, the
duration of intake and source (e.g. physician prescription)
were analysed with regard to the five different BMI groups.
Table 1 Sociodemographic sample description
a
All (N = 14, 592) With drug utilisation (N = 5, 815)
Age (3.00-17.98 years) Mean (SE) 10.9 (0.03) 10.9 (0.06)
Sex male 7, 445 (51.4%) 2, 714 (46.8%)
BMI group Very underweight (< P3) 280 (1.9%) 117 (1.9%)
(Kromeyer-Hauschild Underweight (P3- < P10) 752 (5.1%) 300 (5.2%)
et al. 2001)[25] Normal weight 11, 357 (77.9%) 4, 491 (77.5%)
Overweight, not obese (P90-P97) 1, 306 (8.7%) 537 (8.9%)
Obese (> P97) 897 (6.4%) 370 (6.5%)
Migration status Migrant 2, 201 (17.3%) 708 (13.9%)
Non-migrant 12, 330 (82.7%) 5, 083 (86.1%)
Health insurance Statutory insurance 12, 813 (89.1%) 5, 119 (88.6%)
Private insurance 1, 384 (10.7%) 575 (11.3%)
Other/no insurance 23 (0.1%) 7 (0.1%)
Socioeconomic status (Winkler 1998) [31] Low SES 4, 096 (28.0%) 1, 514 (26.4%)
Medium SES 6, 797 (45.6%) 2, 765 (46.0%)
High SES 3, 699 (26.5%) 1, 536 (27.7%)
aPercentage and mean values were calculated using weighted data.
BMI, body mass index; SE, standard error; SES, socioeconomic status.
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pared between BMI groups and tested for significance
using Kruskal-Wallis tests.
In order to account for non-normality of the cost data,
confidence intervals (CIs) were estimated for each BMI
group applying a non-parametric bootstrap approach
using a percentile method [38].
The association between BMI group and utilisation as
well as costs was examined using multiple generalised
mixed regression models. To analyse the relationship
between BMI and the number of pharmaceuticals, we
compared the performance of models using different dis-
tribution assumptions. A negative binomial model showed
a better fit to the data than a Poisson model or a general-
ised Poisson model (based on pseudo-likelihood), so a
negative binomial model was chosen. Although a large
proportion of children without drug intake might be a
problem, comparing the observed distribution of the num-
ber of pharmaceuticals and the distribution of the pre-
dicted values from the model indicated a satisfactory fit to
the data. Also, the additional calculation of a hurdle model
on drug utilisation barely affected the results regarding
BMI.
We report the exponents of regression estimates that
can be interpreted as factors.
To allow for the typically skewed distribution of costs
and the high proportion of participants without costs, a
two-step model was applied [39]. As a first step, the asso-
ciation of BMI and the probability of drug intake was ana-
lysed. Reducing the analysis to cases with drug intake and
therefore positive costs, in a second step, the association
of BMI and total costs was analysed using a gamma model
with log-link function [40,41]. The modified Park test sup-
p o r t e dt h ec h o i c eo ft h eG a m m ad i s t r i b u t i o n( p=0 . 5 8 ) ,
and the Hosmer-Lemeshow-Test (p = 0.90), the Pregibon
Link-Test (p = 0.80) as well as the Pearson Correlation
Test (p = 0.58) all confirmed the choice of the log link
function.
All regression analyses were adjusted for the variables
sex, age, SES (low, medium or high), as well as migrant
status. These variables were shown to have an important
impact on the utilisation of pharmaceuticals in a previous
study [26]. To allow for a possible non-linear relationship,
a quadratic term for age was added. As data collection was
slightly more frequent in the autumn (29.7%) and winter
(24.6%) than in the spring (22.4%) and summer (23.2%),
we additionally adjusted our analyses for seasonal effects
to avoid possible confounding, even though seasonal dif-
ferences between BMI groups were not significant overall.
The sample point was included as a random effect, and
sample weights were used to account for the complex
sample design.
To show the importance of pharmaceutical costs in chil-
dren and adolescents, mean annual pharmaceutical costs
were added to further cost components (hospital stays,
physician and therapist visits), that were reported in an
earlier article [19]. For this, we used a subsample of 14,
075 participants where information on both, pharmaceuti-
cal and non-pharmaceutical utilisation was available. 95%
confidence intervals were again estimated based on a non-
parametric bootstrap approach.
Statistical analyses were performed using the software
SAS (SAS Institute Inc., Cary, NC, USA, version 9.2),
and the significance level for all analyses was 5%.
Results
Utilisation of pharmaceuticals by BMI groups
T h em e a np r e v a l e n c eo fd r u gi n t a k ei ss l i g h t l yh i g h e r
among overweight and obese children (both 40.9%) com-
pared with normal weight (39.7%) children and adoles-
cents (overall Chi
2 test for differences between BMI
groups not significant). These differences are more dis-
tinct in the ATC groups G (genito-urinary system and
sex hormones), M (musculo-skeletal system) and N (ner-
vous system). The mean number of drugs also increases
slightly from normal weight (0.59) to obese (0.61) chil-
dren. However, the overall Kruskal-Wallis test for differ-
ences between BMI groups was not significant. This
increase was observed especially in the ATC groups G
(genito-urinary system and sex hormones), H (systemic
hormonal preparations, excluding sex hormones and
insulins), J (antiinfectives for systemic use), M (musculo-
skeletal system) and N (nervous system). Further analyses
of utilisation patterns shows that obese children have a
higher percentage of drugs prescribed by a physician (p =
0 . 0 4 )a n das o m e w h a t( b u tn o ts i g n i f i c a n t l y )h i g h e rp e r -
centage of long-term (> 1 year) medication (p = 0.15)
compared with normal weight children.
Regarding the results of the regression model, BMI,
sex, age, SES and migrant status are significantly asso-
ciated with the number of pharmaceuticals taken during
1 week: overweight and obese children take more drugs
than normal weight children (difference significant only
for obese children), and girls take more pharmaceuticals
than boys. The effect of age is U-shaped. Moreover, drug
utilisation is higher for children with medium and high
SES and a non-migrant background. Comparing these
results with a model including all the pharmaceuticals
that were mentioned (before limiting the pharmaceuticals
definition by excluding vitamins, etc.) reveals that the
effect of BMI becomes stronger, whereas the effect of
SES is less important after the exclusion. The results of
the two regression models are summarised in Table 2.
Costs by BMI groups
Table 3 shows mean costs (per week and per year) by
BMI group. The relationship between BMI and drug
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Page 4 of 10costs is U-shaped with a minimum in the normal weight
group.
The results of the two-step regression analysis of phar-
maceutical costs (Table 4) suggest that the likelihood of
drug intake does not differ significantly between BMI
groups (step 1) but, considering only those children who
took a medicine (step 2), there are BMI related differences
in the amount of costs: compared with normal weight
children, costs for obese children are 24% higher. In addi-
tion, the positive estimate for higher SES is only significant
in the second step of the model. Girls have a higher prob-
ability of incurring costs than boys but, if they take a drug,
the mean costs are lower. Age shows a significant associa-
tion with the probability of incurring costs, but not with
the total costs in the second step. Children with a migrant
background have a lower probability of incurring costs at
all but, if they do, costs are higher than in the non-migrant
group.
Separate analyses for age groups (3-6, 7-10, 11-13, 14-
17 years) show no significant differences for overweight
and obese children regarding the probability of incurring
costs (step 1) in all age groups, and significantly higher
costs for the obese regarding total costs (step 2) in all
age groups except in the 11- to 13-year-olds.
Sensitivity analysis
To assess the sensitivity of cost results to changes in the
assumptions, alternative approaches concerning seasonal
differences, pharmacy discounts and package size were
applied. Accounting for seasonal differences in data col-
lection by weights led to an increase in total costs of
0.6%. The inclusion of pharmacy discounts resulted in
costs decreasing by 8.7%. The strongest effect was visible
for the alternative assumption concerning package sizes:
taking the smallest package available (usually N1) as a
basis for cost estimation would lead to an increase in
Table 2 Number of pharmaceuticals - results of regression analysis
Number of drugs (after exclusion) Number of drugs (before exclusion)
Parameter Exp(Est) Pr > |t|
e Exp(Est) Pr > |t|
e
Intercept 1.472 < 0.0001 1.608 < 0.0001
Sex: female 1.225 < 0.0001 1.145 < 0.0001
Age 0.796 < 0.0001 0.820 < 0.0001
Age squared 1.011 < 0.0001 1.009 < 0.0001
BMI
a: very underweight 1.080 0.0332 1.160 0.0891
underweight 1.070 1.091
overweight 1.077 1.035
obese 1.140** 1.060
Socioeconomic status
b: high 1.099** 0.0154 1.234*** < 0.0001
medium 1.075* 1.121***
Season
c: spring 0.944 0.1102 0.935 0.0178
summer 0.270* 0.848**
autumn 0.951 0.955
Migrant
d 0.773*** < 0.0001 0.739*** < 0.0001
N = 14, 531.
Negative binomial model, random effect: sample point, dependent variable: number of pharmaceuticals.
Reference:
anormal weight;
blow socioeconomic status;
cwinter;
dnon-migrant.
ep-value of total effect.
Significance levels for individual effect levels: *** < 0.001, ** < 0.01, * < 0.05.
BMI, body mass index.
Table 3 Drug costs (in €) by BMI groups
Weighted means
N = 14, 592
Mean pharmaceutical costs/week Mean pharmaceutical costs/year
Mean 95% CI
a Mean 95% CI
a
Very underweight 7.54 [3.04-16.87] 392 [158-877]
Underweight 4.54 [3.49-5.82] 236 [181-303]
Normal weight 3.27 [3.03-3.54] 170 [158-184]
Overweight 3.31 [2.75-3.95] 172 [143-205]
Obese 4.06 [2.98-5.60] 211 [155-291]
Total 3.47 [3.22-3.76] 181 [167-195]
aConfidence intervals (CIs) were estimated based on 5, 000 bootstrap replications.
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if the analysis only included physician-prescribed drugs.
However, although all these changes affected the total
costs, the differences between BMI groups remained
similar. Figure 1 illustrates the results of sensitivity ana-
lyses in total and by BMI group.
Total costs per year
In a previously published article mean costs for hospital
stays as well as physician and therapist visits per year
were reported as € 442 [19]. Based on this study, phar-
maceutical costs would add another 41% to that
amount, resulting in total mean annual costs of € 623
Table 4 Pharmaceutical costs - results of two-step regression analysis
1. Probability
a
N = 14, 531
2. Amount of costs
b
N = 5, 791
Parameter Odds ratio Pr > Chi
2g Exp(est) Pr > |t|
g
Intercept - - 9.5571 < 0.0001
Sex: female 1.351 < 0.0001 0.849 < 0.0001
Age 0.728 < 0.0001 0.970 0.1559
Age squared 1.015 < 0.0001 1.000 0.6812
BMI
c: very underweight 1.006 0.3100 2.461*** < 0.0001
underweight 1.077 1.387***
overweight 1.129 1.049
obese 1.122 1.237**
Socioeconomic status
d: high 1.075 0.4349 1.144** 0.0283
medium 1.034 1.069
Season
e: spring 0.960 0.3520 0.973 0.7188
summer 0.869 1.152
autumn 0.955 0.900
Migrant
f 0.673*** < 0.0001 1.144* 0.0144
aLogistic mixed regression;
bGeneralised linear mixed regression model (Gamma distribution with log-link);
Reference:
cnormal weight,
dlow socioeconomic status,
ewinter,
rnon-migrant.
gp-value of total effect.
Significance levels for individual effect levels: *** < 0.001, ** < 0.01, * < 0.05.
BMI, body mass index.
Figure 1 Sensitivity analyses (mean costs per week in €).
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Page 6 of 10(95% CI [579-671]). Figure 2 displays the mean annual
total costs for the five BMI-groups. In total, mean
annual costs were significantly higher for overweight
and obese participants compared to the normal weight
group (p < 0.0001).
Discussion
The primary aim of this study was to explore the associa-
tion between BMI and the utilisation of pharmaceuticals
and costs in German children and adolescents. There is
no significant correlation between BMI group and the
probability of drug utilisation. However, the number of
pharmaceuticals used is 14% higher for obese children
compared with normal weight children. Furthermore,
there is a positive trend to physician-prescribed medica-
tion in obese children and adolescents. Regarding those
children with drug use, costs are 24% higher for obese
children compared with the normal weight group. Thus,
a positive association of childhood obesity and drug utili-
sation and costs is already visible in children and adoles-
cents. A comparison with physician, therapist and
hospital costs shows that pharmaceutical costs make an
important component of total healthcare costs in chil-
dren and adolescents.
This is the first study estimating the excess drug costs
resulting from obesity based on a representative cross-
sectional sample of the German child and adolescent
population using a bottom-up approach. One of the main
advantages of this approach is the possibility of compar-
ing utilisation and costs in population subgroups, for
example with respect to sociodemographic variables and
BMI. Although analyses based on comprehensive admin-
istrative statistics might give better estimates of the actual
level of expenditure for the respective institutions, they
are mostly not a representative sample of the population
and do not include patients’ out-of-pocket expenditures.
However, in the German healthcare system, out-of-
pocket expenditures are especially relevant for pharma-
ceuticals. Furthermore, these studies often do not include
clinical data, such as measured weight for height, and are
therefore limited to cases of diagnosed obesity.
However, several limitations of this study must be
pointed out. Most importantly, analyses were based on a
cross-sectional survey. Therefore, the results allow for
conclusions concerning correlations, but not causal rela-
tionships. While obesity was shown to increase the risk
of numerous health problems, some illnesses might also
induce weight gain. This sample included underweight
children and adolescents, although these were not the
focus of our analyses. The results show that very under-
weight children and adolescents cause the highest mean
costs, but also had the highest standard deviation.
Though underweight is not associated with the probabil-
ity of incurring costs, there is a significantly positive asso-
ciation with total costs. However, on account of the
relatively small percentage of cases, the results for this
group should be interpreted with caution. High pharma-
ceutical costs resulting from low weight seem plausible
as extreme underweight might lead to an impaired
immune system [42]. However, causality is again unclear,
as extreme underweight might also be a consequence of
severe or enduring illness, which itself implies increased
Figure 2 Mean total annual costs (in €).
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of causality, longitudinal data are required.
Although the problem of recall error should be small
considering the short time period, it cannot be excluded
as participants are asked to provide information retro-
spectively - in this case, to state the utilisation of pharma-
ceuticals for the previous 7 days. Moreover, the results
may not be fully representative of the total population
with regard to sociodemographic characteristics. These
cross-regional differences were reduced by post-stratifi-
cation weighting for age, sex, region and nationality [23].
Furthermore, as about 34% of those contacted did not
respond to the survey, non-response bias cannot be
excluded. Costs may be underestimated, because very
sick children might not have taken part in the study.
However, extensive non-response analyses have been
conducted that show only moderate differences in socio-
demographic as well as health-related characteristics
[23]. As far as non-response is explained by age, sex,
region or nationality, it is accounted for by using the
respective weights. Statistical analyses did not include
adjustments for comorbidities. Correlation between
health problems and overweight is not trivial; thus, the
excess cost approach tries to capture all the differences
between the analysed BMI groups.
Regarding the estimation of drug costs, several assump-
tions were necessary that may have caused over- or
underestimation of costs. The estimation of pharmaceuti-
cal costs was based on the DDD, as suggested by the
WHO. However, this measure tends to overestimate drug
consumption: first, if pharmaceuticals are not specifically
for children, the DDD refers to the daily dose for adults;
second, it presumes full compliance. Furthermore, the
frequency of drug intake was estimated based on the four
response categories ‘daily’ and ‘several times a day’,
‘often, but not daily’ and ‘l e s so f t e nt h a no n c ep e rw e e k ’.
It is not clear how this affects cost results. Yet, data for a
more precise population-based assessment of pharma-
ceutical costs are not available so far.
Sensitivity analyses were performed regarding package
sizes, seasonal effects and legal price discounts. Discount
contracts between the pharmaceutical industry and
healthcare insurers could not be taken into account,
because they are not publicly available. Although all
these changes affected the extent of costs in total, none
affected the differences between BMI groups.
In this study, we estimated the costs for drug con-
sumption, not actual expenditures, which might be even
higher, if packages are only partly used and leftovers are
thrown away. As utilisation of pharmaceuticals was
requested for the last 7 days, the extrapolated yearly
cost estimates should be interpreted with caution.
SES (based on parental income and education) was
included as a confounder in statistical analyses because
it may influence health care utilisation as an ‘enabling
factor’ [43]. Yet, it has to be noted that SES may also be
associated with overweight and obesity, but the direction
of the causal relationship is not clear [44,45]: Although
low income might have a negative impact on health
behaviour resulting in weight gain, overweight and obe-
sity in adults could also impede labour market outcomes
and cause lower wages [46] - in our case this is only
relevant if we assume a high correlation of the weight
status of parents and their children. However, a recalcu-
lation of the regression model without SES as a con-
founding variable did not change our results.
The medical literature often questions BMI as a valid
and accurate measure of overweight and obesity [47].
Especially for younger children, alternative approaches
have been proposed with a slightly higher sensitivity
[48]. However, the information required to compute the
BMI is easy to collect and common in a number of
social science data sets. A recently published study sug-
gests that BMI serves as a good surrogate marker for
obesity in population studies [49].
Conclusion
This study complements the existing literature and pro-
vides new country-specific evidence on the relevance of
childhood overweight and obesity as a health problem in
Germany. A positive association of obesity and drug utili-
sation and costs is already visible in children and adoles-
cents. Thus, our results suggest that obese children
should be classified as a priority group for prevention.
Prevention programmes with sustainable positive medical
effects have a high likelihood of being evaluated as cost-
effective. Yet, further research on the long-term relation-
ship between obesity and related healthcare utilisation
and costs is essential to answer the question of causality
and to improve the evidence needed for economic
evaluations.
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